SARS-CoV-2 vaccines in development
- PMID: 32967006
- DOI: 10.1038/s41586-020-2798-3
SARS-CoV-2 vaccines in development
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years.
Comment in
-
Infection and Inflammation of Genitourinary Tract.J Urol. 2021 Jul;206(1):139-140. doi: 10.1097/JU.0000000000001812. Epub 2021 Apr 21. J Urol. 2021. PMID: 33881342 No abstract available.
Similar articles
-
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.Vaccine. 2020 Jun 26;38(31):4783-4791. doi: 10.1016/j.vaccine.2020.05.064. Epub 2020 May 25. Vaccine. 2020. PMID: 32507409 Free PMC article.
-
The underdog coronavirus vaccines that the world will need if front runners stumble.Nature. 2020 Sep;585(7825):332-333. doi: 10.1038/d41586-020-02583-z. Nature. 2020. PMID: 32908297 No abstract available.
-
Coronavirus vaccines get a biotech boost.Nature. 2020 Jul;583(7817):647-649. doi: 10.1038/d41586-020-02154-2. Nature. 2020. PMID: 32694847 No abstract available.
-
The COVID-19 vaccine development landscape.Nat Rev Drug Discov. 2020 May;19(5):305-306. doi: 10.1038/d41573-020-00073-5. Nat Rev Drug Discov. 2020. PMID: 32273591 No abstract available.
-
Prospects for a safe COVID-19 vaccine.Sci Transl Med. 2020 Nov 4;12(568):eabe0948. doi: 10.1126/scitranslmed.abe0948. Epub 2020 Oct 19. Sci Transl Med. 2020. PMID: 33077678 Review.
Cited by
-
A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic.Front Immunol. 2021 Feb 26;12:631139. doi: 10.3389/fimmu.2021.631139. eCollection 2021. Front Immunol. 2021. PMID: 33717166 Free PMC article. Review.
-
Therapeutic Vaccines and Nucleic Acid Drugs for Cardiovascular Disease.J Lipid Atheroscler. 2024 Sep;13(3):328-337. doi: 10.12997/jla.2024.13.3.328. Epub 2024 Jun 24. J Lipid Atheroscler. 2024. PMID: 39355408 Free PMC article. Review.
-
Antibody response to SARS-CoV-2 vaccination is extremely vivacious in subjects with previous SARS-CoV-2 infection.J Med Virol. 2021 Jul;93(7):4612-4615. doi: 10.1002/jmv.26982. Epub 2021 Apr 8. J Med Virol. 2021. PMID: 33788281 Free PMC article.
-
SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.Cell Host Microbe. 2021 Apr 14;29(4):522-528.e2. doi: 10.1016/j.chom.2021.03.008. Epub 2021 Mar 20. Cell Host Microbe. 2021. PMID: 33789085 Free PMC article.
-
Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2.Pathogens. 2022 Sep 12;11(9):1035. doi: 10.3390/pathogens11091035. Pathogens. 2022. PMID: 36145467 Free PMC article.
References
-
- Zhu, N. et al. A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous